Eris Lifesciences
Overview
Eris has outpaced the Indian Pharmaceutical Market (IPM) growth with a CAGR of 19.7% in Chronic+Subchronic and 13.7% in Acute therapy segment. Our field force productivity of INR 4.1 Lac (YPM – Yield per Man per Month) is industry-leading and we are amongst the most productive companies in the Industry.Our product portfolio is primarily focused on therapeutic areas which are treated by super-specialist and specialist doctors such as Diabetologists, Endocrinologists, Cardiologists, Gastroenterologists, and Neurologists. Super specialists and specialists contribute to 86.3% of our total prescriptions as compared to 62.6% for the IPM.
About Us
Eris has outpaced the Indian Pharmaceutical Market (IPM) growth with a CAGR of 19.7% in Chronic+Subchronic and 13.7% in Acute therapy segment. Our field force productivity of INR 4.1 Lac (YPM – Yield per Man per Month) is industry-leading and we are amongst the most productive companies in the Industry.Our product portfolio is primarily focused on therapeutic areas which are treated by super-specialist and specialist doctors such as Diabetologists, Endocrinologists, Cardiologists, Gastroenterologists, and Neurologists. Super specialists and specialists contribute to 86.3% of our total prescriptions as compared to 62.6% for the IPM.
Vision
towards improving health care outcomes and adding value for all our stakeholders including patients, doctors, regulators, employees and business partners.
Mission
to become most admired company by doctors, patients, employees and all channel partners.
Headquarters
Ahmedabad,Gujarat